Arrowhead Pharmaceuticals (ARWR) Stock Forecast & Price Target

Arrowhead Pharma is supported by two major fundamental drivers: strong clinical validation across its RNAi platform and a pipeline that is increasingly de-risked by reproducible, differentiated efficacy data. ARO-MAPT showed mean CSF total tau reductions of up to 73% at Day 105 with no serious TEAEs, while plozasiran delivered 79% to 81% median triglyceride reductions at Month 12 and cut adjudicated pancreatitis events by 78%, strengthening the case for multiple near-term regulatory opportunities. Despite continuing cash burn and possible future dilution, the company’s FDA STAR pilot entry, preserved Priority Review Voucher worth about $215 million, and breadth of partnered and wholly owned CNS programs support a favorable long-term outlook.

Arrowhead Pharma is vulnerable because deeper knockdown has not translated into better efficacy, with response plateauing above 6.4 mg/kg and diranersen’s lowest dose performing best in phase II, suggesting limited room for meaningful upside from dose escalation. Its outlook is further pressured by continuing cash burn, the likelihood of needing to raise additional capital, and the risk that any equity financing could dilute stockholders, while funding may not be available on acceptable terms. On top of that, the company faces major clinical, regulatory, intellectual property, and competitive threats across RNAi and adjacent gene-therapy platforms, where larger rivals and negative trial outcomes could materially impair valuation.